News - Part 2

JPM Meeting Notes – BriaCell Therapeutics (BCT.V)

BriaCell Therapeutics (BCT.V) anticipates getting the 24-patient Phase 2a study up and enrolling patients by the end of the quarter. That’s good news because even though it’s a small and early-stage program, it’s a big potential value driver on both the market and business development side. BriaCell is moving aggressively toward combination therapy with BriaVax™…

JPM Meeting Notes – Actinium Pharmaceuticals (ATNM)

During my meeting with Actinium Pharmaceuticals (ATNM) we delved deeper into the topic I covered via a separate article last week – the clinical hold placed on Seattle Genetics SGN-CD33A. I can go into a lot more detail if necessary, but I think if investors read that article above they will get the picture. I do not…

What Does SGEN’s Clinical Hold On CD33A Mean For Actinium?

Last week, Seattle Genetics (SGEN) announced that it had received notice from the U.S. FDA that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML). The clinical holds were initiated to evaluate the potential risk of hepatotoxicity in patients who…

A Look At Cancer Immunotherapy And Some Key Players In 2017

Cancer immunotherapy, exploiting the abilities of the immune system to treat cancer, is fast becoming the standard of care for many malignancies and offers the best hope for curing patients of their disease. For biotech investors, the prospect of curing cancer has led to an abundance of opportunities as more and more companies enter the…

VistaGen Licenses Regenerative Medicine Technology To BlueRock Therapeutics

BlueRock Is $225M Stem Cell Therapy Startup Funded By Bayer and Versant Ventures On December 14, 2016, VistaGen Therapeutics (NASDAQ: VTGN) announced the company has sublicensed certain rights to its proprietary human pluripotent stem cell (hPSC) technology platform to BlueRock Therapeutics, a newly formed joint venture between Bayer AG and Versant Ventures seeded with $225…

Cannabis Industry Should Benefit From The 21st Century Cures Act

On December 7, 2016, the U.S. Senate passed the 21st Century Cures Act. President Obama said he plans to sign the bill into law as soon as it hits his desk. The Act, which is designed to facilitate FDA approval of new drugs and medical devices, is a major win for the Pharmaceutical and Medical…

Vaxil Bio’s ImMucin is a Novel Neoantigen With Significant Anticancer Potential

Immunotherapy is intended to train and harness the body’s own immune system in order to recognize and target disease. Many approved immunotherapies are quickly becoming physicians best hope in the battle against cancer. While chemotherapy was once thought to be a breakthrough, immunotherapies have come to the forefront due to the targeted efficacy and less…

Cerecor Phase 2 Failure Opens Door for Competitors

On November 29, 2016, Cerecor, Inc. (CERC) reported top-line results from a Phase 2 study examining CERC-301 as an adjunctive therapy for the treatment of depression. The study failed to show a statistically significant separation from placebo. In fact, the placebo was superior to the 12 mg dose of CERC-301 using the Bech-6 subset of…

Vitality Biopharma Taking Cannabinoid Research To The Next Level

Sales of both medical marijuana and adult legal marijuana are soaring. Total marijuana sales in 2014 were less than $5 billion. A story in USAToday notes the number is expected to approach $23 billion in 2020 (1) due to decriminalization and the increasing recognition of its therapeutic utility within the medical community. Twenty-nine states plus…

Interview With Neurologist and ALS KOL Sheds Light on Brainstorm’s Potential With NurOwn

BrainStorm Cell Therapeutics (NASDAQ: BCLI) is a biopharmaceutical company developing adult stem cell therapies for a range of neurodegenerative diseases, with an initial focus on Amyotrophic Lateral Sclerosis (ALS). The company has a proprietary technology that uses a novel differentiation protocol such that mesenchymal stem cells (MSCs) are converted into neurotrophic factor-secreting cells (MSC-NTF cells,…